FDA's Generics Chief Steps Down Citing Political Pressure, And The Agency's Rare Disease Plan Faces Its First Test
Sutter noted that repurposing has become an administration priority, citing recent work on a Leucovorin labeling change and a Reagan-Udall Foundation meeting on repurposing.